For your skin
A safer, slower-acting alternative to prescription-strength dark-spot faders. Built for long-term use without irritation.
Want the science? Keep reading ↓Mechanism of action
Hydroquinone-glucoside that competitively inhibits tyrosinase without releasing free hydroquinone.
Why we tier this moderate
5 cited papers across 3 countries. The mechanism is well-described and there's at least one controlled trial in the literature, but we tier this Moderate rather than Strong to stay honest about how many specific papers we cite directly.
Layering matrix
Compare with
Cited research
Ma ZY, Lu Y, Melanin synthesis and regulation in vivo and commonly used melanin inhibitors from natural products and traditional Chinese medicine, Zhongguo Zhong Yao Za Zhi (China Journal of Chinese Materia Medica) 2020;45(24):5898-5916 — Beijing University of Chinese Medicine review classifies arbutin among tyrosinase-active-site-targeting melanin inhibitors
Morag M et al., A double-blind, placebo-controlled randomized trial of Serratulae quinquefoliae folium, a new source of β-arbutin, in selected skin hyperpigmentations, Journal of Cosmetic Dermatology 2015 — 76% of melasma patients showed clinical lightening over 8 weeks
Kim H, Choi HR, Kim DS, Park KC, Topical hypopigmenting agents for pigmentary disorders and their mechanisms of action, Annals of Dermatology 2012;24(1):1-6 — review classifies arbutin among hypopigmenting agents via tyrosinase regulation as a hydroquinone alternative
Seo DH et al., Biotechnological production of arbutins (alpha- and beta-arbutins), skin-lightening agents, and their derivatives, Applied Microbiology and Biotechnology 2012;95(6):1417-1425 — review documenting arbutin glycosylated hydroquinones as competitive tyrosinase inhibitors producing skin-whitening effect with improved safety vs hydroquinone
Ertam I et al., Efficiency of ellagic acid and arbutin in melasma: a randomized, prospective, open-label study, Journal of Dermatology 2008 — arbutin (and ellagic acid) formulations effectively reduced melasma severity
Sources: 10 clinical journals and regulatory databases across the US, EU, Korea, Japan, and China. Every entry points to a specific document. See methodology for the full list and what each outcome label means.